These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 18268027)

  • 1. Wheat germ cell-free system-based production of malaria proteins for discovery of novel vaccine candidates.
    Tsuboi T; Takeo S; Iriko H; Jin L; Tsuchimochi M; Matsuda S; Han ET; Otsuki H; Kaneko O; Sattabongkot J; Udomsangpetch R; Sawasaki T; Torii M; Endo Y
    Infect Immun; 2008 Apr; 76(4):1702-8. PubMed ID: 18268027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody profiles to wheat germ cell-free system synthesized Plasmodium falciparum proteins correlate with protection from symptomatic malaria in Uganda.
    Kanoi BN; Takashima E; Morita M; White MT; Palacpac NM; Ntege EH; Balikagala B; Yeka A; Egwang TG; Horii T; Tsuboi T
    Vaccine; 2017 Feb; 35(6):873-881. PubMed ID: 28089547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Pfs25 expressed from multiple soluble expression platforms for use as transmission-blocking vaccine candidates.
    Lee SM; Wu CK; Plieskatt J; McAdams DH; Miura K; Ockenhouse C; King CR
    Malar J; 2016 Aug; 15(1):405. PubMed ID: 27515826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate.
    Ntege EH; Arisue N; Ito D; Hasegawa T; Palacpac NMQ; Egwang TG; Horii T; Takashima E; Tsuboi T
    Vaccine; 2016 Nov; 34(46):5612-5622. PubMed ID: 27692771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterologous Expression and Evaluation of Novel
    de Jong RM; Singh SK; Teelen K; van de Vegte-Bolmer M; van Gemert GJ; Stone WJR; Locke E; Plieskatt J; Theisen M; Bousema T; Jore MM
    Front Immunol; 2022; 13():909060. PubMed ID: 35812379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
    Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
    Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Algae-produced Pfs25 elicits antibodies that inhibit malaria transmission.
    Gregory JA; Li F; Tomosada LM; Cox CJ; Topol AB; Vinetz JM; Mayfield S
    PLoS One; 2012; 7(5):e37179. PubMed ID: 22615931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoscreening of Plasmodium falciparum proteins expressed in a wheat germ cell-free system reveals a novel malaria vaccine candidate.
    Morita M; Takashima E; Ito D; Miura K; Thongkukiatkul A; Diouf A; Fairhurst RM; Diakite M; Long CA; Torii M; Tsuboi T
    Sci Rep; 2017 Apr; 7():46086. PubMed ID: 28378857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malaria transmission-blocking vaccines: wheat germ cell-free technology can accelerate vaccine development.
    Miura K; Tachibana M; Takashima E; Morita M; Kanoi BN; Nagaoka H; Baba M; Torii M; Ishino T; Tsuboi T
    Expert Rev Vaccines; 2019 Oct; 18(10):1017-1027. PubMed ID: 31566026
    [No Abstract]   [Full Text] [Related]  

  • 10. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.
    Miura K; Keister DB; Muratova OV; Sattabongkot J; Long CA; Saul A
    Malar J; 2007 Aug; 6():107. PubMed ID: 17686163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.
    Wu Y; Ellis RD; Shaffer D; Fontes E; Malkin EM; Mahanty S; Fay MP; Narum D; Rausch K; Miles AP; Aebig J; Orcutt A; Muratova O; Song G; Lambert L; Zhu D; Miura K; Long C; Saul A; Miller LH; Durbin AP
    PLoS One; 2008 Jul; 3(7):e2636. PubMed ID: 18612426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults.
    Chichester JA; Green BJ; Jones RM; Shoji Y; Miura K; Long CA; Lee CK; Ockenhouse CF; Morin MJ; Streatfield SJ; Yusibov V
    Vaccine; 2018 Sep; 36(39):5865-5871. PubMed ID: 30126674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A highly infectious Plasmodium yoelii parasite, bearing Plasmodium falciparum circumsporozoite protein.
    Zhang M; Kaneko I; Tsao T; Mitchell R; Nardin EH; Iwanaga S; Yuda M; Tsuji M
    Malar J; 2016 Apr; 15():201. PubMed ID: 27068454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malaria Derived Glycosylphosphatidylinositol Anchor Enhances Anti-Pfs25 Functional Antibodies That Block Malaria Transmission.
    Kapoor N; Vanjak I; Rozzelle J; Berges A; Chan W; Yin G; Tran C; Sato AK; Steiner AR; Pham TP; Birkett AJ; Long CA; Fairman J; Miura K
    Biochemistry; 2018 Feb; 57(5):516-519. PubMed ID: 29323879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses.
    Jones RM; Chichester JA; Manceva S; Gibbs SK; Musiychuk K; Shamloul M; Norikane J; Streatfield SJ; van de Vegte-Bolmer M; Roeffen W; Sauerwein RW; Yusibov V
    Hum Vaccin Immunother; 2015; 11(1):124-32. PubMed ID: 25483525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Murine model for assessment of Plasmodium falciparum transmission-blocking vaccine using transgenic Plasmodium berghei parasites expressing the target antigen Pfs25.
    Mlambo G; Maciel J; Kumar N
    Infect Immun; 2008 May; 76(5):2018-24. PubMed ID: 18316385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fusion to Tetrahymena thermophila granule lattice protein 1 confers solubility to sexual stage malaria antigens in Escherichia coli.
    Agrawal A; Bisharyan Y; Papoyan A; Bednenko J; Cardarelli J; Yao M; Clark T; Berkmen M; Ke N; Colussi P
    Protein Expr Purif; 2019 Jan; 153():7-17. PubMed ID: 30081196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.
    Talaat KR; Ellis RD; Hurd J; Hentrich A; Gabriel E; Hynes NA; Rausch KM; Zhu D; Muratova O; Herrera R; Anderson C; Jones D; Aebig J; Brockley S; MacDonald NJ; Wang X; Fay MP; Healy SA; Durbin AP; Narum DL; Wu Y; Duffy PE
    PLoS One; 2016; 11(10):e0163144. PubMed ID: 27749907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles.
    Kumar R; Ray PC; Datta D; Bansal GP; Angov E; Kumar N
    Vaccine; 2015 Sep; 33(39):5064-71. PubMed ID: 26299750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit Plasmodium falciparum transmission.
    McGuire KA; Miura K; Wiethoff CM; Williamson KC
    Malar J; 2017 Jun; 16(1):254. PubMed ID: 28619071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.